Mangoceuticals Shares Soar on Market Manipulation Probe and PeachesRx Launch
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Mangoceuticals Inc (NASDAQ: MGRX), known in Korean as 망고슈티컬스, is a Dallas-based telemedicine company focused on men’s health and wellness. On November 13, 2025, its shares closed at $2.23, representing a 26.70% increase with a trading volume of 13,602,662 shares.
Corporate Structure
Founded in Dallas, Texas, Mangoceuticals operates with a team of 2–10 employees as of late 2025. The executive leadership includes Jacob Cohen (Co-Founder and Chief Executive Officer), Amanda Hammer (Chief Operating Officer), and Eugene M. Johnston (Chief Financial Officer). The board of directors includes Dr. Kenny Myers and Lorraine D’Alessio. Jacob Cohen brings more than 20 years of investment banking and capital markets experience, having advised multiple companies in healthcare, IT, and financial services.
Telemedicine by Mary Eineman
Recent Developments and News
On December 4, 2024, Mangoceuticals initiated an investigation into potential stock manipulation following its October 16, 2024, reverse stock split, citing irregular trading patterns and an increase in shareholder accounts.
A Schedule 13D/A filing dated September 30, 2025, disclosed that Jacob D. Cohen beneficially owns 2,044,356 shares, representing 14.6% of the outstanding stock, while The Tiger Cub Trust holds 911,023 shares, amounting to 6.8%. On October 29, 2025, the company filed an 8-K covering corporate actions under Items 1.01, 1.02, 2.03, 3.02, 5.02, and 9.01. A subsequent 8-K on November 13, 2025, addressed Items 8.01 and 9.01.
Strategic expansions in 2025 include the launch of PeachesRx, a women’s telehealth platform, and the acquisition of Smokeless Technology IP to enter the nicotine pouch market.
Financial and Strategic Analysis
Mangoceuticals’ trailing twelve-month revenue is reported at $516,000 against a net loss of $15.08 million. The balance sheet indicates $101,000 in cash with a debt-to-equity ratio of 3.27%. With a beta of 2.39, the stock exhibits volatility relative to the market. Negative earnings per share (–$3.54) preclude a P/E ratio. The company's valuation multiples are as follows:
| Metric | Value |
|---|---|
| Market Cap | $19.67M |
| Price/Sales (ttm) | 16.0 |
| Price/Book (mrq) | 1.02 |
| Revenue (ttm) | $516k |
| Net Income (ttm) | –$15.08M |
| Cash (mrq) | $101k |
| Debt/Equity (mrq) | 3.27% |
The company’s telemedicine model focuses on erectile dysfunction, hair growth, hormone replacement, and weight management. The introduction of PeachesRx expands its addressable market to include women's health. High valuation multiples reflect expectations of growth, while ongoing cash burn indicates a need for additional financing or achieving operational profitability.
Market Position and Industry Context
Telemedicine for men’s health is a growing segment within digital health, driven by consumer preferences for privacy and convenience. Competitors include established telehealth platforms and specialty pharmacies. Mangoceuticals’ targeted offerings and partnerships with direct-to-consumer compounding pharmacies differentiate it, but revenue scale remains modest. Regulatory scrutiny of telehealth prescribing practices and the outcome of the stock manipulation investigation will influence investor confidence and market access.
TL;DR
On November 13, 2025, MGRX shares rose 26.70% to $2.23 amid high trading volume. The company is investigating possible market manipulation linked to its October 16, 2024, reverse split. Jacob Cohen holds a 14.6% stake as per a September 30, 2025, Schedule 13D/A filing. In 2025, Mangoceuticals launched PeachesRx for women’s telehealth and acquired Smokeless Technology IP for pouch products. Financials show $516k in annual revenue, a $15.08 million net loss, and limited cash reserves, with future growth reliant on revenue expansion, capital raising, and regulatory outcomes.